Antiretroviral-induced toxic epidermal necrolysis in a patient positive for human immunodeficiency virus

Clinical and Experimental Dermatology

Volumn 34, Issue 8, 2009, Pages

  Pahk, R ^a   Azu, M C ^a   Taira, B R ^a   Sandoval, S ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; BACITRACIN; DARUNAVIR; IMMUNOGLOBULIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; TENOFOVIR;

ADULT; ARTICLE; BURN; CASE REPORT; CLINICAL FEATURE; CONVALESCENCE; DESQUAMATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERSENSITIVITY; INTUBATION; LABORATORY TEST; MACULOPAPULAR RASH; MALE; MOUTH ULCER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN BIOPSY; TOXIC EPIDERMAL NECROLYSIS;

ADULT; ANTIVIRAL AGENTS; DIDEOXYNUCLEOSIDES; EPIDERMAL NECROLYSIS, TOXIC; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; RISK FACTORS; STEVENS-JOHNSON SYNDROME; SULFONAMIDES; TREATMENT OUTCOME;

EID: 72549119546     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2009.03508.x     Document Type: Article

References (13)

1. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006 55 : 9 16.
2. Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 2003 83 : 1 9.
3. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994 331 : 1272 1285.
4. O'Neil WM, Drobitch RK, MacArthur RD et al. Acetylator phenotype and genotype in patients infected with HIV. discordance between methods for phenotype determination and genotype. Pharmacogenetics 2000 10 : 171 182.
5. Valdez-Madruga J. TMC114/r is well tolerated by treatment-experiences patients in POWER 1, 2, and 3: integrated clinical safety analysis. Presented at the 16th International AIDS conference, Toronto, 2006.
6. Foster RH, Faulds D. Abacavir. Drugs 1998 55 : 729 736.
7. Trent J, Halem M, French LE, Kerdel F. Toxic epidermal necrolysis and intravenous immunoglobulin: a review. Semin Cutan Med Surg 2006 25 : 91 3.
8. Prins C, Kerdel FA, Padilla RS et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003 139 : 26 32.
9. Claes P, Wintzen M, Allard S et al. Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully with a combination of intravenous immunoglobulins and N-acetylcysteine. Eur J Intern Med 2004 15 : 255 258.
10. Phan TG, Wong RC, Crotty K, Adelstein S. Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. Australas J Dermatol 1999 40 : 153 157.
11. Tan A, Tan HH, Lee CC, Ng SK. Treatment of toxic epidermal necrolysis in AIDS with intravenous immunoglobulins. Clin Exp Dermatol 2003 2 : 269 271.
12. Bossi P, Roujeau JC, Bricaire F, Caumes E. Stevens-Johnson syndrome associated with abacavir therapy. Clin Infect Dis 2002 35 : 902.
13. Montero M, Garcia-Gibert L, Gimenez-Arnau AM, Knobel H. Toxic epidermal necrolysis associated with abacavir. Enferm Infecc Microbiol Clin 2005 23 : 247.